Agent for treating and preventing iron-deficiency conditions in animals

FIELD: veterinary.

SUBSTANCE: agent is based on complex compound of colloidal iron liganded by polyoxymethylene-lauric alcohol and contains following components, mg: colloidal iron 50.0-60.0, lauric alcohol 0.1-0.3, copper 0.1-0.3, zinc 0.1-0.3, cobalt 0.1-0.3, selenium 0.001-0.005, and water to 1000. Agent can further contain 30.0-50.0 mg glucose and 0.1-0.6 mg polyvinyl alcohol.

EFFECT: enabled therapeutical and preventive efficiency at low toxicity, the same dispersity, and high stability upon storage.

3 tbl, 7 ex

 

The invention relates to the field of veterinary medicine and relates to means for the treatment and prevention of diseases of animals caused by a deficiency in their body iron, mainly deficiency anemia, secondary anemia, as well as to improve the safety and productivity of agricultural and carnivores.

Nutritional anemia (physiological anemia, iron deficiency anemia is a disease characterized by a disorder of the blood-forming organs in young animals. This disease is found mainly in autumn, winter and early spring periods, mainly in piglets aged from 5 to 35 days and less frequently in young animals of other species. The diseased animals note the reduction in the formation of red blood cells, low hemoglobin, decreased resistance to other disease that causes significant economic losses to the pig industry. In most households the mortality of 10-15% (1).

The main cause of nutritional anaemia in modern conditions is the deficiency arising from the mismatch between the rate of growth of infants and supply of trace elements with mother's milk. In addition, disturbance absorption of iron contributes to the lack of intake of vitamin B12, C, folic acid, protein and micronutrients is of abalta, copper, iodine, selenium, manganese, etc.

On the background of anemia in piglets develop immunodeficiency age, leading to inhibition of erythropoiesis, the emergence of secondary diseases of the digestive and respiratory systems.

In a patient with anaemia of young violated oxidative processes and develops tissue hypoxia, which leads to the development of degenerative changes of the internal organs. Therefore, anemia invited to consider how it was studied the process associated with impaired activity of many organs and body systems of animals (2).

For the treatment and prevention of nutritional anaemia use of iron preparations for intramuscular and oral administration.

Almost all known iron-containing preparations are poorly tolerated, causing indigestion. While the severity of diarrhea is stronger, the more will remain in the intestine nevsosavchegosa iron. In this regard, it is impossible to carry out a course to the end and achieve the desired results.

Injectable drugs are mostly complex iron compounds with ligands of different origin: polyhydric alcohols (sorbitol), dextran, dextrin, etc. that enter the animal alone or with the addition of various sets of salts of microe the of elements.

Known drug “Feroglobin for the treatment and prevention of nutritional anaemia, containing a complex compound of iron with low molecular weight dextran and water in an effective ratio (3).

Known drug Farbital for the treatment and prevention of iron deficiency containing compound salt of iron sorbitol, citric acid, dextrin as a stabilizer and water in an effective ratio (4).

Well-known medication for the treatment and prevention of anemia containing compound, hydrate, chloride of iron with hydrazinehydrate and water in an effective ratio (5).

Well-known medication for the treatment and prevention of anemia, containing a complex compound of iron with starch and water in an effective ratio (6).

Well-known medication for the treatment and prevention of nutritional anaemia, containing a complex compound of iron with a polymeric ligand and water. As a polymer ligand used compounds obtained by the reaction of hydroxycarboxylic acid, a polyhydric alcohol and epoxysilane, or products obtained by the reaction of sucrose, polyhydric alcohol and epoxysilane in effective relation (7).

Known drug “Microraman for the treatment and prevention of nutritional anaemia containing compound jelly is and with low molecular weight dextran, copper, cobalt and water in an effective ratio (8).

Known drug “Biofer” for the prevention of nutritional anaemia containing liquid aloe Vera and water solution feroglobin in effective relation (9).

Known drug “Ferox” for the prevention of nutritional anaemia, representing the Hanks solution, enriched cationic iron concentrations of 1.0± 0,15% (10).

Well-known drug for the prevention of nutritional anaemia piglets containing the complex compound of iron with low molecular weight dextran, copper, cobalt, selenium, and water (11).

Well-known medication for the treatment and prevention of anemia, containing a complex compound of iron with physiologically active polymer and water (12).

Well-known medication for the treatment and prevention of iron-deficiency anemia of various etiologies, containing a complex compound of iron with sorbitol, sucrose and water (13).

Well-known medication for the treatment and prevention of iron deficiency anemia in farm animals containing complex compounds of zinc and iron from raw sugar cane and water (14).

Well-known medication for the treatment and prevention of iron deficiency anemia in farm animals containing complex compounds of zinc and iron with beet sugar and water (15).

Known drug “Suiferrovit” Leche for the tion and prevention of nutritional anaemia, containing inactivated normal serum of pigs, the complex compound of iron with low molecular weight dextran, cobalt, copper, calcium, vitamin B1In2B6PP and water (16).

Known drug “Ursoferran-100 for the treatment and prevention of nutritional anaemia, containing as active ingredient the complex of iron (III)-dextran heptenophos acid and phenol as preservative (17).

Also known medication Brij-35” (polyoxyethyleneglycol alcohol of General formula C12H25(Och2CH2)2n·HE, n=23 used in clinical and research laboratories for quick cleaning and washing autoanalyzer (18, 19).

The closest to the proposed invention, the essential features is the drug “Bioperine for the treatment and prevention of iron deficiency in animals containing compound colloidal iron with gluconic acid as a ligand, minerals and water, and in 1000 ml of solution contains: Fe (III) 50 mg, cu (II) 0.16 mg, Zn (II) 0.1 mg, With (II) of 0.12 mg Se 0,00015 mg, NaCl 0.9 mg and water - the rest (20).

The disadvantages of the known drugs, including drug-prototype, are limited in their therapeutic and prophylactic efficacy and toxicity, caused a significant presence in their SOS is Ave unbound iron, the size heterogeneity of the particles of iron-containing complexes and a dispersity (formation of agglomerates) and stability during storage, resulting in incomplete absorption of iron in the lack or violation of producing bioactive substances hemostimulating of diseased animals.

In the task of creating the present invention was the development of a drug for treatment and prevention of iron deficiency in animals with high therapeutic and prophylactic efficacy, good tolerability, low toxicity, maintaining the dispersion and high stability during storage.

The technical result from use of the present invention is to expand the Arsenal of drugs for the treatment and prevention of iron deficiency in animals with high therapeutic and prophylactic efficiency by reducing the toxicity, good endurance, conservation dispersion and high stability of iron-containing complex during storage.

This technical result is achieved by creating a product for the treatment and prevention of iron deficiency in animals, characterized by the following set of features.

The proposed product contains the complex compound colloides the iron ligand, the set of trace elements and water, and as it contains ligand polyoxyethyleneglycol alcohol, and the trace elements copper, zinc, cobalt and selenium in the following ratio of ingredients, mg:

Colloidal iron 50,0-60,0

Polyoxyethyleneglycol alcohol of 0.1-0.3

Copper is 0.1-0.3

Zinc of 0.1-0.3

Cobalt is 0.1-0.3

Selenium 0,001-0,005

Water to 1000,0

If necessary to improve iron absorption in the body of the animal, we offer the drug may contain additional glucose is preferably in the amount 30,0-50,0 mg

If necessary to create the body of the animal depot offer drug it may contain additional polyvinyl alcohol preferably in quantities of 0.2-0.6 mg

The present invention includes the following set of essential features that provide technical result, in all cases, which sought legal protection:

1. Drug for the treatment and prevention of iron deficiency in animals.

2. Colloidal iron in quantity 50,0-60,0 mg

3. Polyoxyethyleneglycol alcohol as a ligand in an amount of 0.1 to 0.3 mg.

4. Copper in an amount of 0.1 to 0.3 mg.

5. Zinc in the amount of 0.1-0.3 mg

6. Cobalt in an amount of 0.1 to 0.3 mg.

7. Selenium in the amount of 0.001-0.005 mg

8. Water in an amount up to 1000,0 mg.

Features of the invention, x is describing the proposed drug and its matching with the characteristics of the prototype, including a generic term that reflects the assignment are:

1. Drug for the treatment and prevention of iron deficiency in animals.

2. Compound colloidal iron ligand.

3. The copper.

4. The zinc.

5. The cobalt.

6. Selenium.

7. Water.

Compared with drug-prototype a distinctive feature of the proposed drug is that, as a ligand, it contains polyoxyethyleneglycol alcohol.

The present invention also contains other distinctive signs, expressing a particular form of execution or specific conditions of its use:

1. The drug contains additional glucose is preferably in the amount 30,0-50,0 mg

2. The preparation additionally contains polyvinyl alcohol preferably in quantities of 0.2-0.6 mg

The proposed product expands the Arsenal of drugs for the treatment and prevention of iron deficiency in animals has a high therapeutic and prophylactic efficiency by reducing the toxicity, good portability, preservation of dispersion and stability of iron-containing complex during storage.

The achievement of the technical result of the proposed use of the drug is due to the fact that the result of the interaction of colloidal particles of iron from polyoxyethylenated the m alcohol it causes a strong physical-chemical bond, leading to the formation of colloidal particles of iron surface with hydrophilic properties, which gives the particles of the complex pharmacological properties. The degree of hydrophilization particles of colloidal iron was estimated by the heat of interaction of initial ingredients.

Processing of colloidal iron polyoxyethylenesorbitan alcohol in the claimed concentration range allows you to get the iron-containing complex uniform in size and maintain it in dispersed and stable condition for a long time. The compound obtained withstands boiling and repeated freezing to -20° With subsequent thawing.

In addition, the presence of the proposed drug glucose in the inventive concentration improves the absorption of iron in the body of the animal.

The presence of the proposed preparation of polyvinyl alcohol in the inventive concentration allows you to create the body of the animal depot of the drug after its introduction. Adsorbed on the particles of iron-containing complex molecules of polyvinyl alcohol to form around particles of complex solantie shell and make the suspension of the complex in a kinematically stable form, which leads to the formation of a depot of the drug at its introduction into the body of the animal. The drug is deposited in the liver and blood bodies. De is onirovanie of the product ensures a better distribution of the active substance in the animal body, the prolongation of his actions, does not cause adverse effects on tissue and shortens the treatment of sick animals. The drug enhances the redox reactions and hematopoiesis, enhances the synthesis of hemoglobin, myoglobin, increases the permeability of cell membranes, stimulates water-salt metabolism, and action microelements.vichy (selenium, iron, cobalt, copper and zinc) enzymes.

Conducted by the applicant's analysis of the prior art, including searching by the patent and scientific and technical information sources, and identify sources that contain information about the analogues of the proposed drug has allowed to establish that the applicant had not found the source, which is characterized by signs, identical to all the essential features of the proposed drug. The definition from the list of identified unique prototype as the most similar set of features analogue has allowed to establish the essential towards perceived by the applicant to the technical result of the distinctive features in the proposed drug set forth in the claims.

Therefore, the proposed drug meets the condition of patentability “novelty”.

To check compliance with the proposed drug condition pentacosane and “inventive step” by the applicant conducted an additional search of the known solutions for the symptoms of, included in the characterizing portion of the independent claim.

Drugs for the treatment and prevention of iron deficiency in animals is known. Information about them, see “state of the art description of the present invention. A distinctive feature of the proposed drug is introduced in its composition polyoxyethyleneglycol alcohol in an amount of 0.1 to 0.3 mg of the Specified characteristic is functionally independent.

Know the use of polyoxyethyleneglycol alcohol for quick cleaning and washing autoanalyzer in clinical and research laboratories (18, 19).

The inventors have discovered a new property polyoxyethyleneglycol alcohol in the claimed range of concentrations to stabilize colloidal iron to give it the pharmacological properties and agitative sustainable form of a suspension of iron-containing complex during prolonged storage.

The search results showed that the proposed solution does not follow for the expert in the obvious way from the prior art, as set out in the description section (not identified solutions having attributes matching a set of distinctive features of the present invention), and revealed no effect provided by the combination of essential features of PR is degenova invention transformations to achieve a technical result.

Therefore, the proposed drug meets the condition of patentability “inventive step”.

The effectiveness of the proposed drug illustrated by examples of its use, which does not restrict the scope of the invention.

Example 1.

Iron chloride (Fl3·6N2O) in the amount of 15.5-16.0 kg dissolved in 30 l of distilled water. The resulting solution is filtered and transferred into the reactor. Continuous operation of the stirrer in the reactor serves a thin stream of a saturated solution of ammonium carbonate [NH4(CO3)2] at an average speed of 100 cm3/min in volume 22-25 l to establish the pH of the reaction mixture in the range of 6.8 to 7.2. In the process of introducing into the reactor a saturated solution of ammonium carbonate in the range of pH values of 3.3 to 3.8, a gel is formed colloidal iron, which is broken by intensive mixing and adding a saturated solution of ammonium carbonate.

The resulting solution of colloidal iron is subjected to ultrafiltration with simultaneous dialysis tap water to release the colloidal solution of iron chloride from ammonium (NH4Cl2) and carbon dioxide (CO2), resulting from the reaction of ferric chloride with ammonium carbonate. The end of dialysis is determined by the absence of chlorine ions in the water coming out of ultrafiltration the apparatus in the reaction with silver nitrate (gNO 3). After dialysis, the pH of the colloidal solution of iron set in the range from 9.0 to 9.2 by addition of 10% solution of sodium hydroxide (NaOH) and with constant stirring, the reaction mixture is left for 8-10 hours. After that the reaction mixture is neutralized by adding citric acid to pH 6.5-6.8 and heated to 80-85° without turning off the stirrer. At this time the color of the reaction mixture changed from red-brown to dark red (black) opalescense with the formation in solution of the black cone, which indicates the receipt of colloidal iron. To obtain the iron-containing complex in a hot solution of colloidal iron make a mixture of polyoxyethyleneglycol alcohol, glucose and polyvinyl alcohol so that the final concentration polyoxyethyleneglycol alcohol, glucose and polyvinyl alcohol in 1000 mg of the drug was 0.1 to 0.3; 30,0-50,0 and 0.2-0.6 mg, respectively. As a result of interaction of colloidal particles with iron polyoxyethylenesorbitan alcohol in the inventive concentrations it causes a strong physical-chemical bonds, leading to the preservation of dispersion and stability of iron-containing complex during storage and the formation of colloidal particles of iron surface with hydrophilic properties, which gives the particles of the obtained complex farmacologiche is the cue properties.

Glucose in the claimed range of concentrations used in the product to improve iron absorption in the body of the animal.

Polyvinyl alcohol in the claimed concentration range used to create the body of the animal depot offer drug after its introduction.

The content of colloidal iron in 1000 mg of the drug should be 50,0-60,0 mg if the concentration of colloidal iron is different from the above, the solution is concentrated or diluted by ultrafiltration installation.

After that, the solution is cooled to 60° C, filtered through an ion-exchange resin, measure the size of the complex and add to it a set of microelements in the form of their salts: CuSO4·5H2O, ZnCl2, CoCl2·6H2O and PA2SO3- so that the content of C++, Zn++and Co++in 1000 ml of the drug was 0.1-0.3 mg, a Se in the range of 0.001-0.005 mg In this case, each salt is dissolved separately in 0.5 l of distilled water, the solution is brought to a boil and boiling the solution make a thin stream into the solution of the iron complex with vigorous stirring. The optimal formulation of the proposed drug is given in table 1.

The resulting preparation is subjected to chemical and biological control.

Iron in the structure of the prep the ATA identify complex metric titration with sulfosalicylic acid. Copper, zinc, cobalt and selenium determined using atomic absorption spectrophotometer “Saturn” according to GOST 15150-69. The drug is produced in aqueous solution, representing a dark brown liquid with a pH of about 6.5-6.8. The drug should be stored in glass or plastic bottles. Store in containers made of ferrous metals or aluminum is unacceptable because of its corrosiveness.

Acute toxicity and maximum tolerated dose of the drug for laboratory animals was determined according to the “guidance on determining the toxic properties of drugs used in veterinary medicine and animal husbandry”, approved by the Ministry of health of the USSR, agricultural Sciences and BS Gosagroprom USSR. LD50for white mice weighing 18,0-20,0 g was 1.02 cm3/goal. According to the accepted classification of the drug belongs to slightly toxic.

The offered drug is used for treatment and prevention of diseases of animals caused by a deficiency in their body iron, mainly deficiency anemia, secondary anemia, increasing safety and productivity of agricultural and carnivores.

Before you use a bottle of medication was thoroughly shaken. The drug is administered to the animals by intramuscular injection in the neck or thigh once daily.

Prophylactic drug enter the t animals in the following doses:

- sheep, goats 15 days prior to lambing, 5000,0 mg;

- sows 15 days prior to farrowing 10000,0 mg;

- cows 15 days before calving 1000,0-2000,0 mg per 40 kg body weight;

- pigs on 2-4 day life 2000,0 mg;

- calves at 3-4-day lives of 3,000 .0 mg;

- dogs 500.0 mg per 10 kg of live weight;

- the holes in the mating period for 300,0 mg

For therapeutic purposes, the drug is administered twice with an interval of 7-14 days in the following doses:

- pigs of 200.0 mg/kg BW;

- calves, lambs 100.0 mg/kg body weight;

- dogs 1000,0 mg per 10 kg of live weight;

cats 200.0 mg/kg BW;

- mink 500.0 mg on the head.

Example 2.

Studies of the proposed product made as described in example 1 toxicity in laboratory animals.

The whole experience was used by 60 white mice and 1 rabbit with average live weight of 16-18 g and 2.5 kg, respectively.

Tested dose from 250,0 to 1700,0-2000,0 mg/goal. three methods of administration: cutaneous application of a rabbit, subcutaneous and oral administration of white mice.

As a result of researches it is established:

1. Cutaneous double rubbing of the drug to the rabbit does not have dermonecrotic actions.

2. Bioassays on white mice at oral 3-time administration of the drug in doses of 250.0 and 500.0 mg/goal. not set its toxic action.

3. In the acute experience of PR is the introduction into the stomach of mice high doses of the drug by the method of Cerberus determined the median lethal dose LD 50that caused within 24 hours of the toxic effect is fatal 50% of the animals. The research results are summarized in table 2. LD50the drug is 1020,0 mg/goal.

In accordance with the indicator on the scale of the toxicity of the drug belongs to toxic substances.

The use of the drug in doses 700,0-1700,0 mg/goal. manifested by changes in the General condition of white mice, i.e. with increasing the dose increases the toxic effect of the drug.

Clinical manifestation of toxic effects of high doses of the drug occurs within 7-10 minutes after injection. While there was a sharp depression, rapid breathing, shaking or strong muscular twitching, increased sensitivity to external stimuli, jumping on a hot frying pan, beeping. Part of the animals died from doses 1000,0-1200,0 mg/goal. after 40-50 min after injection, doses 1400,0-1700,0 mg/goal. within 30 minutes

4. Subcutaneous administration of the drug in doses of 250.0 and 500.0 mg/goal. did not cause toxic effects and death of the mice. The introduction of the drug in the dose 700,0 mg/goal. caused a mild degree of oppression, disappearing after 30 minutes From doses 1000,0; 1500,0 and 2000,0 mg/goal. observed mortality of mice.

5. Multiple (within 25 days) oral administration of the drug to mice at a dose of 250.0 mg/goal. had no harmful toxic effects on mice, which then indicates the absence of cumulative properties of the drug.

As a result of research on laboratory animals has revealed that the drug belongs to low-toxic compounds and has no dermonecrotic and cumulative effect.

Example 3.

Tested the effectiveness of the proposed drug, manufactured as described in example 1 and containing mg:

Colloidal iron 50,0

Polyoxyethyleneglycol alcohol 0,1

Glucose 30,0

Polyvinyl alcohol 0,2

Copper 0,1

Zinc 0,1

Cobalt 0,1

Selenium 0,001

Water to 1000,0

in the conditions of one of the farms of the Ivanovo region in the treatment of small animals with alimentary hypochromic anemia.

The proposed medication was prescribed for small pet blood loss in the postoperative period 1000,0 mg per kg of body weight three times during the month, with an interval of 10 days. In experiment 5 was used dogs breed average dog and 3 cats. With the introduction of this drug in the postoperative period was easily marked by rapid tissue regeneration and healing of joints, restore appetite, mobility of animals, allergic and toxic effects to the drug is not installed.

In the use of drug complications local or General nature were not observed.

Thus, the proposed preparatation to treat animals with anemia, caused by blood loss and circulatory disorders.

Example 4.

Comparative trials of the effectiveness of the proposed drug, manufactured as described in example 1 and containing mg:

Colloidal iron 55,0

Polyoxyethyleneglycol alcohol 0,2

Glucose 40,0

Polyvinyl alcohol 0,4

Copper 0,2

Zinc 0,2

Cobalt 0,2

Selenium 0,003

Water to 1000,0

and drug “Feroglobin-75” in one of the farms of the Ivanovo region on livestock piglets three days of age with nutritional hypochromic anemia. In the experience used 25 goals. The observation period of 20 days. The animals were divided into three groups: 1 group of 10 animals for testing of the proposed drug, 2 groups of 10 animals for testing “Feroglobin-75 and 3 groups of 5 goals served as a control and was not subjected to the treatment of iron-containing drug. Pigs from groups 1 and 2 was administered to subjects iron supplements on 1500,0 mg intramuscularly in the neck region. After 10 days was made repeated administration of the same dose.

As a result of researches it is established that the proposed drug allows to maintain the safety of piglets at 100%, it increases the growth rate of piglets, daily biomass growth was 4.8, and 9.6% more than the animal the control group. When using “Feroglobin-75 results were similar. In the control group not treated with iron therapy, the safety population was 60%, and the surviving piglets were characterized by retarded growth and development.

Example 5.

Comparative trials of the effectiveness of the proposed drug, manufactured as described in example 1 and containing mg:

Colloidal iron 55,0

Polyoxyethyleneglycol alcohol 0,2

Glucose 40,0

Polyvinyl alcohol 0,4

Copper 0,2

Zinc 0,2

Cobalt 0,2

Selenium 0,003

Water to 1000,0

and drug Ursoferran-100” (Germany) in terms of one of the farms of the Ivanovo region on livestock piglets 3-4 days of age. The drugs were injected animals intramuscularly in the neck at a dose of 1500,0-2000,0 mg. Pre-offer drug was treated with a 1 group of animals in the amount of 6 goals piglets. For piglets were observed for 10 days. During the period of observations of side effects and complications were not observed.

After this drug has been treated group 2 animals in the amount of 65 goals. Observation of the animals was performed for 51 days. During the observation period there were no complications.

The proposed product was treated group 3 animals in the amount of 50 goals. The animals were observed for 1 day. At follow-up complications were observed. At weaning average weight per pig was 12 kg

In parallel with the testing of the proposed drug in the household used the drug “Ursoferran-100” (Germany) 853 heads piglets 3-4 days of age. When the average weaning weight of piglets was also 12 kg

In its action on piglets offered the drug is not inferior to the drug “Ursoferran-100” (Germany).

Example 6.

Tested the effectiveness of the proposed drug, manufactured as described in example 1 and containing mg:

Colloidal iron 50,0

Polyoxyethyleneglycol alcohol 0,1

Glucose 30,0

Polyvinyl alcohol 0,2

Copper 0,1

Zinc 0,1

Cobalt 0,1

Selenium 0,001

Water to 1000,0

in terms of the Perm region in the practice of treatment of iron deficiency in mink.

The treatment was conducted on a group of mink from 20 individuals 12 months of age with obvious signs of necrotic dermatitis (scratching, skin necrosis, damage to the coat). The drug was administered intramuscularly at a dose of 1 000,0 mg per kg of body weight of the animal three times with an interval of 10 days. In parallel conducted tonic and anti-inflammatory therapy.

During the treatment the clinical condition of the animals gradually to 30-day deadline is normalized, and at the end of the treatment period W the animals were moving, well ate food and had no defects of the skin. Safety of animals in the group amounted to 98% with good patinirovannoy assessment. Their hair was characterized as dense adjusted and silky. Allergic and toxic effects to the drug is not installed.

Example 7.

Comparative trials of the effectiveness of the proposed drug is manufactured as described in example 1, containing mg:

Colloidal iron 50,0

Polyoxyethyleneglycol alcohol 0,1

Glucose 30,0

Polyvinyl alcohol 0,2

Copper 0,1

Zinc 0,1

Cobalt 0,1

Selenium 0,001

Water to 1000,0

and drug Bioperine” (prototype) in the conditions of one of the farms Suzdal, Vladimir region on pigs, Sosunov three days of age.

For processing piglets used the proposed drug with a 2-year shelf life, and “Bioperine” - after one year of storage. The proposed drug was administered to pigs-will in doses 1000,0; 2000,0 and 5000,0 mg Drug Bioperine” used as directed.

The dynamics of weight gain of the animals are shown in table 3. Blood was taken from the tail vein immediately before the introduction of drugs in the future after weighing the animals.

As a result of tests it is established that both drugs were mesured the s. The physiological condition of the animals was assessed as good. At the injection site was not detected negative effects of drugs. In some cases, the weight gain of piglets in the group treated with the proposed drug exceeded the weight of animals treated with “Bioperine”, with differences in content of clinical blood parameters in both groups of animals was not found.

After establishing the safety of drugs was conducted advanced treatment 142 piglets, which were introduced, we offer the drug at doses 1000,0 and 2000,0 mg depending on the physiological state of animals. All piglets were alive, their physiological condition was assessed as good.

In similar conditions the drug “Bioperine” were treated 89 piglets. In this group 2 pig fell, and 18 animals were observed swelling at the injection site, which sometimes moved into ulcers. The negative consequences of drug “Bioperine” disappeared after 12-20 days.

Thus, the proposed drug has a more pronounced therapeutic efficacy and long term suitability of the application (2 year period) compared to drug-prototype.

Thus, the above information shows the implementation of the use predlagaemoj the invention the following cumulative conditions:

- the product embodying the invention, intended for use in veterinary medicine;

for the present invention in the form as it is described in the independent claim, confirmed the possibility of its implementation using the steps described in the application or known before the priority date tools and methods;

- when using the proposed drug is achieved technical result provided by the task of invention.

Therefore, the present invention meets the condition of patentability “industrial applicability”.

Sources of information

1. Jonauskas L.D. Prevention of nutritional anemia in piglets using iron-containing drugs added to feed. Abstract of Diss. Kida. veterinary Sciences. - M., 1980

2. Karpati IM Hematology Atlas of farm animals. - Minsk, Uraji, 1986

3. Regulation of production feroglobin (with an iron content of 75 mg/ml). Minsk plant of medical preparations, 1968 - 20 C.

4. Auth. mon. The USSR № 306847 And 61 To 25/02, 21.06.71,

5. Auth. mon. The USSR № 355955 And 61 To 25/02, 23.10.72 g

6. Auth. mon. The USSR № 683745 And 61 To 33/26, 05.09.79,

7. Auth. mon. The USSR № 730276 And 61 To 33/26, 39/00; 25.04.80,

8. Auth. mon. The USSR № 1328956 And 61 To 33/26, 1984

9. Guidance on the application of Biothera” in veterinary medicine. Utverzhdennogo and MA P of the Republic of Belarus, 17.02.95

10. Application No. 92006855/15 patent of the Russian Federation the invention, a 61 K 33/26, 27.02.95,

11. Auth. mon. The USSR № 1797196 And 61 To 33/04, 10.02.96,

12. RF patent № 2079305 And 61 To 33/26, 20.05.97,

13. RF patent № 2098101 And 61 To 33/26, 10.12.97,

14. RF patent № 2188022 And 61 To 33/26, 27.08.02,

15. RF patent № 2188650 And 61 To 33/26, 10.09.02,

16. Index of drugs by their pharmacological action and application. Warsaw. The scientific information centre “Polfa”, 1987. - S.

17. General and clinical veterinary compounding: a Handbook/edited by Prof. Vinculante. - M.: Kolos, 1998. - S.

18. Bed, M., publishing house of the Owls. encyclopedia, 1977, Vol.7, 176-177.

19. Directory Corporation Sigma-Aldrich” Handbook of laboratory reagents and equipment for Russia, 2000-2001, s, catalogue No. 85. 636-6.

20. Veterinary drugs in Russia: a Handbook /Irakleiou, Nuarimol. - M.: Selhozizdat, 2000. - 296-297 (prototype).

Table 1

Optimal formulations of the drug for the treatment and prevention of iron deficiency in animals
Name ingredientsThe recipe mg
MinimumAverageMax
Colloidal iron50,055,060,0
Polyoxyethyleneglycol alcohol0,10,20,3
Glucose30,040,050,0
Polyvinyl alcohol : 0,20,40,6
Copper0,10,20,3
Zinc0,10,20,3
Cobalt0,10,20,3
Selenium0,0010,0030,005
Waterto 1000,0to 1000,0to 1000,0

Table 2

The definition of LD50the proposed drug for white mice
Subjects dose (mg/bird.0,250,50,71,01,21,41,7
Survived a goal.8864310
Palo goal.0024578
Z (number of the fallen) 2 1,03,06,07,5-
d (the interval between doses)0,250,20,30,20,20,3-
Zd-0,20,90,91,22,25-

n=8, ∑ Zd=5.45

LD50=LD100-5,45=1,02 ml/bird.

Table 3

The dynamics of weight gain piglets after applying iron preparations
Name of productDose injection mgThe follow-up period and weight of piglets (kg)
1 day3 dayday 1121 days








Offer medication
1000,01,1

1,1

1,1
2,5

2.4GHz

1,6
4,4

3,8

4,4
6,5

7,5

6,9
Average1,082,174,206,97
2000,01,5

1,0

1,5
1,8

2,5

1,6
4,9

4,8

the 4.7
5,0

5,3

7,5
the Central 1,251,974,80to 5.93
5000,01,6

1,5

1,0
2,3

1,6

2,0
4,5

4,9

4,8
5,5

7,1

7,3
Average1,361,974,736,63
“Bioperine”2000,01,4

1,0

1,1
2,3

1,6

2,0
4,6

3,5

4,2
7,0

6,0

7,0
Average1,171,974,10to 6.67

1. Drug for the treatment and prevention of iron deficiency in animals containing compound colloidal iron ligand, copper, zinc, cobalt, selenium and water, characterized in that, as a ligand, it contains polyoxyethyleneglycol alcohol in the following ratio of components, mg:

Colloidal iron 50,0-60,0

Polyoxyethyleneglycol alcohol of 0.1-0.3

Copper is 0.1-0.3

Zinc of 0.1-0.3

Cobalt is 0.1-0.3

Selenium 0,001-0,005

Water To 1000,0

2. The preparation according to claim 1, characterized in that it additionally contains glucose in the number 30,0-50,0 mg

3. The preparation according to claim 1 or 2, characterized in that it additionally contains polyvinyl alcohol in an amount of 0.2-0.6 mg

/p>

 

Same patents:

FIELD: pharmaceutics, veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating hypomicroelementosis in different farm and domestic animals, furred animals, and, also, for enhancing the growth in animals, and treating a number of specific diseases and, also, for maintaining microelemental composition of feedstuffs. The suggested preparation includes chelated complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with organic ligand of complexone type and water. According to the innovation as a chelation ligand it contains trisodium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid at a certain ratio of components. The innovation provides to obtain preparation in soluble form being capable to be well digested by the animal.

EFFECT: higher efficiency.

FIELD: medicine, pharmacology.

SUBSTANCE: invention relates to method for assay of optimized regimens in dosing erythropoietin (EOR). Invention proposes a system for election of one or some regimens in dosing by using pharmacokinetic/pharmacodynamic (PK/PD) as a model for assay of PK/PD pattern regimens. Then method involves selection of such regimen that provides the serum concentration of EOR exceeding its before administration for 5-30 days between administrations of EOR. Invention provides optimal applying EOR for correction of blood indices changes and treatment of diseases associated with them.

EFFECT: improved and valuable modeling method.

50 cl, 81 dwg, 2 tbl, 8 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new aminobenzophenones of the formula (I):

or their pharmaceutically acceptable salts. These compounds elicit properties of inhibitors of cytokines secretion, in particular, 1β-interleukin (IL-1β) and tumor necrosis α-factor (TNF-α) and to secretion of polymorphonuclear superoxide that are useful for treatment of inflammatory diseases, for example, skin diseases, such as psoriasis, atopic dermatitis. In the formula (I) R1 is taken among the group consisting of halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, cyano-group, carbamoyl, phenyl or nitro-group under condition that when R1 means a single substitute then it at ortho-position, and when R1 means more one substitute then at least one substitute of R1 is at ortho-position; R2 means one substitute at ortho-position being indicated substitute is taken among the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy-group; R3 means hydrogen, halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, phenyl, cyano-, carboxy-group or carbamoyl; R4 means hydrogen atom or (C1-C3)-alkyl; Q means a bond or -SO2-; Y means (C1-C15)-alkyl, (C3-C10)-carbocyclic group or phenyl being each of them can be substituted optionally with one or some similar or different substitutes designated by the formula R5; R5 means halogen atom, (C1-C4)-alkyl, amino-, (C1-C3)-alkoxy-group, (C1-C3)-alkoxycarbonyl or -COOH; X means oxygen or sulfur atom. Also, invention relates to a pharmaceutical composition and to a method for treatment and/or prophylaxis of inflammatory diseases.

EFFECT: valuable medicinal properties of compounds and composition.

9 cl, 2 sch, 2 tbl, 29 ex

FIELD: medicine, phthisiology, anesthesiology.

SUBSTANCE: during the day of operation one should perform autohemotransfusion, then introduce epocrine intravenously by drops at the dosage of 50-200 U/kg patient's body weight; next day after interference one should inject epocrine subcutaneously at the dosage of 25-100 U/kg; at hematocrit level being below 35% 48 h after operation it is necessary to repeat subcutaneous injection of the above-mentioned preparation at the dosage not exceeding 50 U/kg. The present innovation favors hemopoiesis stimulation in postoperational period, that, in its turn, accelerates postoperational rehabilitation in patients of this group and enables, also, to avoid allotransfusions being dangerous because of immunoconflicting reactions.

EFFECT: higher efficiency of compensation.

1 ex, 1 tbl

The invention relates to pharmaceutical industry and relates to a method of producing iron-containing drug for the treatment and prevention of iron deficiency anemia in animals by the interaction of organic acids with gemostimuliruyuschee properties, isolated from extracts of peat, with a hydroxide of iron (11), selected from water-soluble salts of iron (11) the deposition of the alkaline solution with the subsequent laundering of water impurities

The invention relates to preparations for the prevention and treatment of Pets and farm animals, as well as to maintain the microelemental composition of the feed, and can be used in animal breeding and fur farming

The invention relates to experimental medicine, may find application in radiobiological experiments, and further in clinical practice

The invention relates to organic chemistry and pharmacology, and relates new connection - 1-(1,1-dissociator-3)-2-morpholinobenzenediazonium hydrochloride, increasing resistance to acute hypoxia with hypercapnia

The invention relates to biotechnology and is used for the preparation of recombinant human erythropoietin (EPO)
The invention relates to medicine, surgery and intensive care, to a method of replacement of massive blood loss of any Genesis

FIELD: animal science.

SUBSTANCE: one should supplement the diet with microelements. Prophylaxis should be performed during stable and pasture keeping by cycles consisting of 30-60-d-long introduction of microelements and 30-60-d-long interval. Microelements should be added into the diet in their easily digestible form daily as aqueous solution at the quantity of (mg/kg body weight): cobalt chloride 0.02-0.5 mg; manganese chloride 0.05-1.0 mg; potassium iodide 0.002-0.02 mg; water - up to 1 ml. The method enables to prevent urinary losses of biologically valuable substances necessary for animals, increase protein synthesis and assimilation of microelements out of fodders, normalize blood composition and activity of cardio-vascular system, enhance deposition of calcium and phosphorus in bony tissue, increase musculature tonicity, improve total body state and productivity.

EFFECT: higher efficiency of prophylaxis.

5 ex

The invention relates to veterinary

Complex drug // 2228184
The invention relates to the field of medicine

The invention relates to the field of veterinary medicine and can be used for the prevention and treatment calzidefitsitnykh States of animals and birds and to the medical industry, in particular the production of calcium-containing preparations
The invention relates to the fishing industry, in particular to a method for producing a medicinal product from fish liver
The invention relates to medicine
The invention relates to pharmaceutical industry
The invention relates to pharmaceutical industry and can be used as a means, which also serves as a binder, diluent, sliding and lubricating substances in the dosage forms of the vitamin or multivitamin preparations

The invention relates to medicine, in particular tuberculosis, and can be used to limit complications and side effects in the treatment of tuberculosis
Up!